First patient dosed in a phase 2 combined therapy trial for chronic HBV

First patient dosed in a phase 2 combined therapy trial for chronic HBV

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.This multi-center, randomized, open-label study will evaluate the safety and efficacy of BRII-835 (VIR-2218), an investigational small interfering RNA targeting HBV, combined with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, compared with BRII-835 alone. A prior study revealed both agents demonstrated proof of mechanism in HBV patients.“WeRead More

Share on facebook
Share on twitter
Share on linkedin